lobbying_activities: 1948853

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1948853	24e25b3f-6938-4788-be6d-38a3df976712	Q1	RED+BLUE STRATEGIES	400693064	PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)	2017	first_quarter	MMM	S. Con. Res. 3 - Budget Resolution for FY 2017 - Impact of reconciliation instructions on the prescription drug benefit and coverage for those covered through health care marketplaces and Medicaid beneficiaries. S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars.	Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE	60000		0	0	2017-04-05T14:34:39.670000-04:00